Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7U6S0)

Drug Name

1,3,5-triphenylimidazolidine-2,4-dione Drug Info

Synonyms

CHEMBL381136; 61505-60-0; SCHEMBL2791034; CTK2D8602; DTXSID10469422; 1,3,5-triphenylimidazoline-2,4-dione; 2,4-Imidazolidinedione, 1,3,5-triphenyl-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[2]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[3]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[4]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[5]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[6]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[7]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[8]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[9]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[10]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cann... J Med Chem. 2006 Feb 9;49(3):872-82.
2	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
3	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4	Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
5	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
6	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
7	Clinical pipeline report, company report or official report of AstraZeneca (2009).
8	Company report (Gwpharm)
9	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
10	Clinical pipeline report, company report or official report of Bird Rock Bio.
11	Clinical pipeline report, company report or official report of Affimed Therapeutics.